AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
220.61
+2.07 (0.95%)
At close: Sep 26, 2025, 4:00 PM EDT
220.81
+0.20 (0.09%)
After-hours: Sep 26, 2025, 7:53 PM EDT
AbbVie Revenue
AbbVie had revenue of $15.42B in the quarter ending June 30, 2025, with 6.65% growth. This brings the company's revenue in the last twelve months to $58.33B, up 6.05% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$58.33B
Revenue Growth
+6.05%
P/S Ratio
6.69
Revenue / Employee
$1,060,509
Employees
55,000
Market Cap
389.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
ABBV News
- 1 day ago - AbbVie For Healthy Dividend Growth - Seeking Alpha
- 2 days ago - AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease - PRNewsWire
- 3 days ago - AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists - GlobeNewsWire
- 3 days ago - Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai - PRNewsWire
- 5 days ago - These Dividend Stocks Have Big Yields and Are Beating the Odds - Barrons
- 5 days ago - Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality - PRNewsWire
- 6 days ago - These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech - Market Watch
- 11 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga